Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Production of recombinant coagulation factors: Are humans the best host cells?

Full text
Swiech, Kamilla [1, 2] ; Picanco-Castro, Virginia [2] ; Covas, Dimas Tadeu [3, 2]
Total Authors: 3
[1] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Pharmaceut Sci, Sao Paulo - Brazil
[2] Univ Sao Paulo, Reg Blood Ctr Ribeirao Preto, Ctr Cell Based Therapy, Ribeirao Preto, SP - Brazil
[3] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Internal Med, Sao Paulo - Brazil
Total Affiliations: 3
Document type: Review article
Source: BIOENGINEERED; v. 8, n. 5, p. 462-470, 2017.
Web of Science Citations: 4

The main treatment option for Hemophilia A/B patients involves the administration of recombinant coagulation factors on-demand or in a prophylactic approach. Despite the safety and efficacy of this replacement therapy, the development of antibodies against the coagulation factor infused, which neutralize the procoagulant activity, is a severe complication. The production of recombinant coagulation factors in human cell lines is an efficient approach to avoid such complication. Human cell lines can produce recombinant proteins with post translation modifications more similar to their natural counterpart, reducing potential immunogenic reactions. This review provides a brief overview of the most important characteristics of recombinant FVIII and FIX products available on the market and the improvements that have recently been achieved by the production using human cell lines. (AU)

FAPESP's process: 12/04629-8 - Establishment of a production platform for recombinant therapeutic proteins in human cells
Grantee:Kamilla Swiech Antonietto
Support type: Research Grants - Young Investigators Grants
FAPESP's process: 13/08135-2 - CTC - Center for Cell-Based Therapy
Grantee:Dimas Tadeu Covas
Support type: Research Grants - Research, Innovation and Dissemination Centers - RIDC